Internal Medicine, Hematology & Oncology · Los Alamitos, CA
NPI
1831247667
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
3822 Katella Ave Ste 200
Los Alamitos, CA, 90720
Phone (562) 735-0602
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.6M
162,649 services
Medicare patients, 2024
729
Average age 77
Drug cost, 2024
$6.8M
2,239 prescriptions
Company payments, 2025
$13K
From 60 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vu Q Phan was code J3111 (injection, romosozumab-aqqg, 1 mg), 13,440 times for 12 patients. In total Vu Q Phan billed 162,649 services in 97 codes, and Medicare paid $2.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 13,440 | 12 | $8.53 | $115K |
| J0897 Injection, denosumab, 1 mg | Office | 13,260 | 97 | $20.52 | $272K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,900 | 28 | $15.89 | $62K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,976 | 22 | $0.09 | $178 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 892 | 15 | $0.07 | $65.81 |
| 99214 Office E&M - Established | Office | 807 | 297 | $105.19 | $85K |
| 96372 Injection Administration | Office | 651 | 138 | $12.39 | $8,063 |
| 99232 Hospital E&M - Subsequent | Facility | 580 | 159 | $64.79 | $38K |
| 99213 Office E&M - Established | Office | 384 | 246 | $72.54 | $28K |
| 96367 Intravenous Infusion, Hydration | Office | 303 | 30 | $25.29 | $7,664 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 231 | 28 | $4.55 | $1,051 |
| 96413 Chemotherapy Administration | Office | 218 | 28 | $118.05 | $26K |
| 99215 Office E&M - Established | Office | 215 | 109 | $150.06 | $32K |
| 96365 Intravenous Infusion, Hydration | Office | 173 | 72 | $54.34 | $9,401 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 142 | 24 | $0.66 | $93.14 |
By year: 2022 $3.5M for 262,877 services; 2023 $2.3M for 204,557 services; 2024 $2.6M for 162,649 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vu Q Phan prescribed most often to Medicare patients was Anastrozole, with 212 prescriptions and refills. In total Vu Q Phan wrote 2,239 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 212 | 608 | 74 | $4,442 |
| Letrozole Generic | 178 | 450 | 46 | $4,792 |
| Eliquis Apixaban | 160 | 282 | 37 | $159K |
| Hydroxyurea Generic | 73 | 168 | 18 | $1,750 |
| Ondansetron Hcl Generic | 62 | 62 | 32 | $1,041 |
| Zoledronic Acid Generic | 60 | 64 | 11 | $2,658 |
| Prednisone Generic | 60 | 95 | 24 | $386 |
| Dexamethasone Generic | 53 | 63 | 20 | $1,650 |
| Lenalidomide Generic | 52 | 52 | Under 11 | $714K |
| Exemestane Generic | 50 | 127 | 13 | $13K |
| Allopurinol Generic | 49 | 111 | 14 | $360 |
| Imbruvica Ibrutinib | 45 | 45 | Under 11 | $722K |
| Diphenhydramine Hcl Generic | 44 | 44 | Under 11 | $106 |
| Famotidine Famotidine/Pf | 43 | 43 | Under 11 | $56.04 |
| Lupron Depot Leuprolide Acetate | 41 | 123 | 15 | $231K |
Brand drugs: 683 claims; generic drugs: 1,556 claims; opioid claims: 53.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vu Q Phan $13K ($13K in general payments such as food, travel and fees) from 60 companies. The largest payer was Janssen Biotech, Inc. with $3,424.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 16 | $3,424 |
| Stemline Therapeutics Inc. | 4 | $2,553 |
| AstraZeneca Pharmaceuticals LP AZN | 27 | $664 |
| Pfizer Inc. PFE | 22 | $460 |
| Celgene Corporation BMY | 24 | $420 |
| E.R. Squibb & Sons, L.L.C. BMY | 29 | $416 |
| Boston Scientific Corporation BSX | 9 | $382 |
| Incyte Corporation INCY | 14 | $338 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $293 |
| Merck Sharp & Dohme LLC MRK | 9 | $244 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.